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ABSTRACT 
Objective: To investigate the impact of intraoperative blood transfusion on the long-term 
outcomes of liver transplantation for hepatocellular carcinoma. 
Method: Adult patients who had non-salvage liver transplantation at our center between 
January 2005 and December 2012 for hepatocellular carcinomas that were within the UCSF 
criteria and could not be resected or ablated were divided into groups with and without 
intraoperative blood transfusion. Comparisons were made between groups. 
Results: Ninety-nine patients were included in the study. Sixty-two (62.6%) patients 
received intraoperative blood transfusion. Patients without transfusion were younger (54 vs. 56 
years; p=0.04) and had a lower Model for End-stage Liver Disease score (11 vs. 14; p<0.001). 
More of them had stage-1 tumors (64.9% vs. 37.1%; p=0.007) and fewer of them had 
postoperative complications of grade IIIA or above in the Clavien-Dino classification (21.6% vs. 
48.4%; p=0.008). The groups were comparable in hospital mortality (3.2% vs. 2.7%; p=1.00), 
5-year overall survival (90.8% vs. 89.2%; p=0.611), and 5-year disease-free survival (90.5% vs. 
89.2%; p=0.835). On multivariate analysis, postoperative complications of grade IIIA or above 
were associated with worse survival (hazard ratio 7.108; 95% confidence interval 1.455-34.712; 
p=0.015). 
Conclusion: Intraoperative blood transfusion was shown to have no significant impact on 
the long-term outcomes of liver transplantation for hepatocellular carcinoma, whereas 
postoperative complications of grade IIIA or above were associated with worse recipient survival. 
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 Introduction 
It has been reported that blood loss and blood transfusion during hepatectomy for 
hepatocellular carcinoma (HCC) promote disease recurrence and worsen postoperative overall 
and disease-free survival [1-11]. Harmful effects of perioperative blood transfusions on 
recurrence of other malignancies have also been reported [12-25]. It is speculated that 
perioperative blood transfusions cause immunomodulation reactions and thus have a deleterious 
effect on the recurrence of malignancies and the survival of patients. 
The proportion of patients who undergo liver transplantation for HCC is increasing and HCC 
comprises one third of the indications for liver transplantations in Asia [26]. Liver transplantation 
remains a surgical procedure associated with major bleeding despite recently improved 
understanding and management of coagulation defects [27, 28]. The association between blood 
transfusion and recurrence-free survival after transplantation for HCC remains controversial. 
This retrospective study was conducted to investigate the relation between perioperative 
blood transfusion and overall and disease-free survival after liver transplantation for HCC. 
 
Patients and Methods 
Our objective was to investigate intraoperative blood transfusion requirement as a risk factor 
for overall survival after liver transplantation, and to identify independent risk factors associated 
with overall survival using logistic regression. 
Included in the study were adult patients who had non-salvage liver transplantation at the 
Department of Surgery, The University of Hong Kong, for HCCs that were within the UCSF 
(University of California, San Francisco) criteria and could not be resected or ablated. The study 
period was from January 2005 to December 2012. 
The strategies adopted for selection of patients with known HCC for transplantation have 
been described elsewhere [29, 30]. In brief, tumor evaluation was done with computed 
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tomography of the abdomen and thorax, in addition to radionuclide bone scan at initial diagnosis. 
In recent years dual-tracer [11C-acetate and 18F-fluorodeoxyglucose (FDG)] positron emission 
tomography were performed to exclude extrahepatic metastasis. There was no mandatory waiting 
period prior to liver transplantation and bridging therapy with transarterial chemoembolization 
was offered to those listed for liver transplantation with reasonable liver function. 
Trigger for the administration of packed red blood cells was not standardized and relied 
entirely on the assessment of the overall clinical situation by the individual highly experienced 
surgeons in charge. We used only allogenic blood for transfusion and cell-saved blood was not 
used for patients with known hepatocellulcar carcinoma.  
 
Definitions  
Blood transfusion: Only transfusion of red cell concentrate was regarded as blood transfusion. 
Transfusion of other blood products (fresh-frozen plasma, platelets, or albumin) was not 
considered blood transfusion. 
Operative mortality: Death occurring within 30 days of transplantation. 
Complication: Postoperative complications were defined and classified according to the 
modified Clavien-Dindo classification [31]. Briefly, grade I is any deviation from the normal 
postoperative course not requiring any special treatment. Grade II complications are those 
requiring pharmacological treatment. Grade III complications are complications that require 
surgical or radiological intervention with (IIIB) or without (IIIA) general anesthesia. Grade IV 
refers to life-threatening complications involving single (IVA) or multiple (IVB) organ 
dysfunction. Grade V is death of the patient. 
As postoperative complication was concerned, the patients were divided into two groups: 
those with no complications or only grade-I or grade-II complications, and those with 
complications of grade III or above. In the case of multiple complications in a patient, the 
5 
 
5 
 
complication grade was based on the most serious complication. 
 
Statistical analysis  
Continuous variables were expressed as medians and ranges and compared by the 
Mann-Whitney U test. Pearson’s chi-squared test was used to compare categorical variables. 
Survival analysis was performed using the Kaplan-Meier method and compared between groups 
by the log-rank test. A multivariable analysis by Cox regression (step-wise forward model) was 
performed for variables reaching significance on univariate analysis that impacted upon overall 
survival. All analyses were performed by PASW Statistics for Windows, version 18.0 (SPSS, 
Chicago, IL, USA). Statistical significance was indicated by p values <0.05. 
 
Results 
A total of 99 patients underwent liver transplantation for HCC. The median follow-up period 
was 42.9 (0.9-108.1) months. Amongst them, 61 underwent living donor liver transplantation 
(LDLT) and 38 underwent deceased donor liver transplantation (DDLT). The median waiting time 
to transplantation was 0.89 (0.03-56) months for our LDLT patients and 7.98 (0.03 – 90) months 
for the DDLT patients. 9 (14.8%) and 18 (47.4%) underwent bridging therapy prior to the LDLT 
and DDLT respectively. 
Intraoperative blood transfusion was given to 62 (62.6%) patients. A comparison of 
demographic and perioperative clinical data between patients with and without intraoperative 
blood transfusion is shown in Table 1. 
Figure 1 and Figure 2 are Kaplan-Meier plots of the overall survival and disease-free survival 
of the patients respectively. Compared with their counterparts, patients who received 
intraoperative blood transfusion showed no differences in terms of hospital mortality (3.2% vs. 
2.7%; p=1.00), 5-year overall survival (90.8% vs. 89.2%; p=0.611), and 5-year disease-free 
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survival (90.5% vs. 89.2%; p=0.835). The 1-year, 3-year and 5-year graft survival was 95.2%, 
95.2% and 90.8% for the patients who received intraoperative blood transfusion and 94.6%, 
89.2% and 89.2% for those without intraoperative blood transfusion (p=0.611). 
Table 2 shows the results of univariate and multivariate analyses of risk factors associated 
with overall survival. On multivariate analysis, the presence of a postoperative complication of 
grade IIIA or above was the only factor associated with worse survival (hazard ratio 7.108; 95% 
confidence interval 1.455-34.712; p=0.015). 
 
Discussion 
It has been reported that blood loss and blood transfusion during hepatectomy for HCC 
promote disease recurrence and worsen postoperative overall and disease-free survival [1-11]. 
Similar findings have also been made with malignancies of the breast, the stomach, and the colon 
and rectum [12-25]. It is speculated that perioperative blood transfusions cause 
immunomodulation reactions and thus have a deleterious effect on the recurrence of malignancies 
and the survival of patients, which was demonstrated in recent studies [30-34]. 
Experimental animal models have suggested that immunomodulation associated with 
allogeneic blood transfusion is primarily related to the infusion of allogeneic leukocytes [35]. It 
may be mediated by allogeneic mononuclear cells, soluble mediators derived from white blood 
cells, and soluble HLA peptides circulating in allogeneic plasma [36]. Transfusion of allogeneic 
whole blood products has been shown to induce variations in certain immune functions [37, 38], 
such as reduced NK cell activity, T lymphocyte blastogenesis, and increased suppressor T 
lymphocyte activity, which may impair host resistance to infection and the spread of neoplastic 
cells. 
Blood loss during liver transplantation is usually high due to portal hypertension and 
intra-abdominal varices as a consequence of end-stage liver failure, in addition to clotting 
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disorders related to liver failure. Even though emphasis has been placed on reducing blood loss 
during the procedure, it still carries a risk of excessive blood loss, which is associated with higher 
risks of mortality, infectious complications, postoperative multi-organ dysfunction, early surgical 
re-intervention, and reduced graft survival [32-41]. Rana et al. [42] recently reported that 
intraoperative blood loss was an important risk factor for mortality after liver transplantation. 
However, studies on the influence of intraoperative allogeneic blood transfusion on cancer 
recurrence and patient survival after transplantation for HCC are scarce, and the topic remains 
controversial [43]. 
In our current study, the long-term (5-year) overall survival and disease-free survival were 
similar between patients with and without intraoperative blood transfusion, which is different 
from results reported by studies on hepatectomy. There may be various reasons. Firstly, although 
all the patients had HCC, those who received hepatectomy and those who received transplantation 
were two distinct groups of patients. In HCC patients undergoing hepatectomy, those who need 
transfusion generally have larger lesions that either are close to the vena cava or require major 
resection, while those who do not need blood transfusion usually have smaller, more peripheral 
lesions that can be resected under close hemostatic control. Various factors (e.g. preoperative level 
of serum alpha-fetoprotein, tumor size, tumor number, tumor cell differentiation, and the 
incidence of vascular invasion or liver cirrhosis) could have biased the results of those studies. 
When clinicopathological biases were adjusted, the overall survival rates of transfused patients 
were not significantly lower than those of non-transfused patients [44, 45]. In our study, all the 
patients were within the UCSF criteria. Although the non-transfused group had significantly more 
stage-I tumors compared with the transfused group, preoperative level of serum alpha-fetoprotein, 
tumor size, tumor differentiation, and the incidence of vascular permeation were comparable 
between the two groups. The major determinant for blood transfusion might be more related to the 
Model for End-stage Liver Disease scores of the patients (a median of 14 in the transfused group 
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vs. 11 in the non-transfused group; p< 0.001) rather than the tumors. 
Secondly, since all the transplant recipients were put on immunosuppressants in the 
postoperative period, the immunomodulatory effect of allogeneic blood transfusion might not be 
as significant as that in patients who received hepatectomy. However, despite the blood 
transfusions and the immunosuppressants, we were able to achieve a 5-year disease-free survival 
rate of 90.5% in the transfusion group and 89.2% in the non-transfused group (p=0.835). 
Thirdly, in spite of the improvement in transplant techniques, blood loss during liver 
transplantation remains an issue. On the contrary, the problem of blood loss during hepatectomy 
has improved greatly. At our center, the overall transfusion rate for hepatectomy was 55.4% 
before 1999 but has reduced to 13.6% after 1999 [46]. A high-volume center in Japan also made a 
similar finding [47]. However, 63% of the transplant recipients in our current study required blood 
transfusion. The relatively small number of non-transfused patients has limited the power of the 
study. 
There is another important finding in this study. The presence of a postoperative 
complication of grade IIIA or above was the only clinicopathological factor with an independent 
influence on overall survival. Postoperative complications may have adverse effects on the 
long-term outcomes of various kinds of surgery, including that for HCC and colorectal cancer [48]. 
In another study, specifically postoperative sepsis was shown to be an independent predictor of 
disease-free and overall survival after hepatic resection for colorectal liver metastasis [49]. The 
mechanism underlying the effects of postoperative complications on overall survival remains to 
be elucidated. It has been postulated that blood transfusion and septic complications might lead to 
a period of immunosuppression, which might in turn lead to disease recurrence and patient death 
[50]. In fact, previous studies have shown a correlation between blood transfusion and 
complication development [51-54]. Further clinicoimmunological studies would be helpful in 
elucidating exactly how postoperative complications increase the risk of poor long-term survival. 
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This study has a number of drawbacks. It has a retrospective nature, a small sample size, and 
a heterogeneous patient population. In addition, it is a single-center study with inevitable selection 
bias. Nonetheless, it has shed some light on the survival outcome of HCC patients with and 
without blood transfusion during liver transplantation. 
 
Conclusion 
Transfusion of allogeneic blood has been reported to be associated with potentially 
devastating complications such as infections, transfusion reactions, and pulmonary edema. 
However, this study has shown that perioperative blood transfusion may not be a poor prognostic 
factor for tumor recurrence and overall survival for recipients of liver transplantation for HCC. 
However, the adverse effect of serious postoperative complications on long-term survival 
outcome has highlighted the importance of good perioperative care and meticulous surgical 
techniques in the avoidance of morbidity. 
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Table 1. Comparison of demographic and perioperative clinical data of the two groups of patients 
 
 With transfusion (n=62) 
No transfusion 
(n=37) P 
Age (years) 56 (30-65) 54 (40-67) 0.040 
Male : Female 48 : 14 34 : 3 0.065 
Etiology 
Hepatitis B virus 
Hepatitis C virus 
Hepatitis B and C viruses 
Cryptogenic 
Alcoholic 
Autoimmune hepatitis 
Primary biliary cirrhosis 
 
45 (72.6%) 
10 (16.1%) 
1 (1.6%) 
2 (3.2%) 
2 (3.2%) 
1 (1.6%) 
1 (1.6%) 
 
32 (86.5%) 
3 (8.1%) 
1 (2.7%) 
0 
1 (2.7%) 
0 
0 
0.055 
Model for End-stage Liver Disease score 14 (6-37) 11 (6-17) <0.001 
Alpha-fetoprotein (ng/ml) 15 (1-11210) 25 (2-3114) 0.483 
Number of tumor 1 (1-3) 1 (1-3) 0.034 
Largest size of tumors (cm) 2.5 (0.9-5.5) 2.3 (1-6.5) 0.772 
Vascular permeation 16 (25.8%) 9 (24.3%) 0.870 
Differentiation 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
No data 
 
19 (30.6%) 
34 (54.8%) 
5 (8.1%) 
4 (6.5%) 
 
16 (43.2%) 
16 (43.2%) 
1 (2.7%) 
4 (10.8%) 
0.347 
 
 
 
 
Tumor-node-metastasis staging 
Stage I 
Stage II 
 
23 (37.1%) 
39 (62.9%) 
 
24 (64.9%) 
13 (35.1%) 
0.007 
 
 
Live donor graft : Deceased donor graft 34 : 28 27 : 10 0.073 
Graft weight (g) 727.5 (395-1800) 650 (350-1975) 0.316 
Cold ischemic time (min) 144 (71-633) 120.5 (82-447) 0.114 
Warm ischemic time (min) 50.5 (26-108) 53 (35-70) 0.356 
Operation duration (min) 663 (300-1086) 671 (344-1027) 0.443 
Blood loss (ml) 4500 (1000-30800) 1300 (500-2000) < 0.001 
Unit of blood transfusion 5 (1-56) 0  
Hospital mortality 2 (3.2%) 1 (2.7%) 1 
Complication (Clavien-Dindo grade IIIA or above) 30 (48.4%) 8 (21.6%) 0.008 
Hospital stay (d) 17 (8-84) 11 (1-65) <0.001 
 
Data are presented in median (range) or number (percentage). 
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Table 2. Results of univariate and multivariate analyses of risk factors associated with overall survival 
 
Variable Univariate analysis Multivariate analysis 
 Hazard ratio (95% confidence interval) P Hazard ratio 
95% confidence 
interval P 
Age 0.9986 (0.896-1.086) 0.780    
Sex 0.754 (0.157-3.631) 0.725    
Hepatitis B virus infection 0.867 (0.178-4.216) 0.860    
Hepatitis C virus infection 0.411 (0.083-2.034) 0.276    
Model for End-stage Liver Disease score 1.060 (0.984-1.142) 0.125    
Alpha-fetoprotein 1.000 (0.999-1.001) 0.747    
Graft type (live donor v. deceased donor graft) 1.063 (0.263-4.302) 0.932    
Blood transfusion 1.059 (0.995-1.128) 0.073    
Complication (Clavien-Dindo grade IIIA or above) 7.108 (1.455-34.712) 0.015 7.108 1.45-34.71 0.015 
Cold ischemic time 1.000 (0.995-1.005) 0.963    
Warm ischemic time 1.011 (0.967-1.058) 0.620    
Operation duration 1.002 (0.999-1.006) 0.233    
Number of tumor 1.445 (0.549-3.804) 0.456    
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